Breast density notification laws are pushing AI supported supplemental screening into the mainstream
Dr. Dereck Mush, MD, MBA
Therapixel
AI-powered software designed to assist radiologists in breast cancer screening.
What they do
The company manufactures FDA-cleared and CE-marked AI software that analyzes mammograms to flag potential malignant microcalcifications and masses. Hospital breast imaging clinics and breast screening centers use the software to improve cancer detection rates and speed up workflows.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Mammography AI imaging
- Product type
- Software as a medical device
- Stage
- Series B
- Headquarters
- Nice, France
- Region
- Europe
- Founded
- 2013
- Total funding
- $23M raised
Notable investors: Credit Mutuel Innovation, Omnes Capital, Ventech, Regimbeau.
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
Point-of-Care Ultrasound Is the Quiet Revolution in Diagnostics
Dr. Dereck Mush, MD, MBA
Does AI Actually Improve Radiology Accuracy? What the Prospective Trials Show in 2026
Dr. Dereck Mush, MD, MBA
Liquid biopsy monitoring is turning precision oncology into a continuous process, not a one time test
Dr. Dereck Mush, MD, MBA